- $13.77m
- -$26.50m
- $43.95m
Hookipa Pharma Inc Reports Results For The Quarter Ended In December: Earnings Summary
Brief: HOOKIPA Reports Fourth Quarter Results, Provides 2023 Outlook
Hookipa Pharma Inc Expected To Post A Loss Of 21 Cents A Share: Earnings Preview
Brief: Hookipa Pharma To Report Fourth Quarter And 2022 Results On March 15
Brief: Hookipa Achieves $10 Million Milestone Payment In Development Of Immunotherapy For Kras-Mutated Cancers
Brief: Hookipa Pharma Inc Receives Minimum Bid Price Requirement Non Compliance Notice From Nasdaq
Hookipa Pharma up on achieving milestone set by Gilead for $5 mln payment
Brief: Hookipa Pharma Achieves $5 Mln Milestone Payment From Gilead Sciences
Hookipa Pharma Inc Reports Results For The Quarter Ended In September: Earnings Summary
Brief: Hookipa Pharma Announces Q3 2022 Financial Results
Hookipa Pharma Inc Expected To Post A Loss Of 28 Cents A Share: Earnings Preview
Hookipa Pharma Inc Expected To Post A Loss Of 28 Cents A Share: Earnings Preview
U.S. STOCKS ON THE MOVE-Lam Research, Cyngn, Par Pacific
U.S. STOCKS ON THE MOVE-Vertiv, U.S. energy, Gold miners
U.S. STOCKS ON THE MOVE-AT&T, Blackstone, HOOKIPA Pharma
U.S. STOCKS ON THE MOVE-Tesla, Xeris Biopharma
HOOKIPA Pharma surges on cancer therapy deal with Roche
Brief: Hookipa Announces Strategic Collaboration And License Agreement With Roche To Develop Novel Arenaviral Immunotherapy For Kras-Mutated Cancers
Hookipa Pharma Inc Reports Results For The Quarter Ended In June: Earnings Summary